ИСПОЛЬЗОВАННАЯ ЛИТЕРАТУРА
1 Mayer EA, Bradesi S, Chang L, Spiegel BM, Bueller JA, Naliboff BD. Functional GI disorders: from animal models to drug development. Gut 2008, 57: 384‒404.
2 Drossman DA, Camilleri M, Mayer EA, Whitehead WE. AGA technical review on irritable bowel syndrome. Gastroen-terology 2002, 123: 2108‒31.
3 Arebi N, Gurmany S, Bullas D, Hobson A, Stagg A, Kamm M. Review article: the psychoneuroimmunology of irritable bowel syndrome ‒ an exploration of interactions between psychological, neurological and immunological observations. Aliment Pharmacol Ther 2008, 28: 830‒40.
4 Belmaker RH, Agam G. Major depressive disorder. N Engl J Med 2008, 358: 55‒68.
5 Dinan TG, Quigley EM, Ahmed SM et al. Hypothalamic-pituitary-gut axis dysregula-tion in irritable bowel syndrome: plasma cytokines as a potential biomarker? Gastroenterology 2006, 130: 304‒11.
6 Shanahan F, Kiely B. The gut microbiota and disease ‒ an inner repository for drug discovery. Drug Discov Today Ther Strat 2007, 4: 195‒200.
7 Forsythe P, Sudo N, Dinan T, Taylor VH, Bienenstock J. Mood and gut feelings. Brain Behav Immun 2010, 24: 9‒16.
8 Rhee SH, Pothoulakis C, Mayer EA. Principles and clinical implications of the brain-gut-enteric microbiota axis. Nat Rev Gastroenterol Hepatol 2009, 6: 306‒14.
9 Parkes GC, Brostoff J, Whelan K, Sanderson JD. Gastrointestinal microbiota in irritable bowel syndrome: their role in its pathogenesis and treatment. Am J Gastroenterol 2008, 103: 1557‒67.
10 Kassinen A, Krogius-Kurikka L, Makivuokko H et al. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology 2007, 133: 241‒33.
11 Amaral FA, Sachs D, Costa VV et al. Commensal microbiota is fundamental for the development of inflammatory pain. Proc Natl Acad Sci USA 2008, 105: 2193‒7.
12 Rousseaux C, Thuru X, Gelot A et al. Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nat Med 2007, 13: 35‒7.
13 Quigley EM, Flourie B. Probiotics and irritable bowel syndrome: a rationale for their use and an assessment of the evidence to date. Neurogastroenterol Motil 2007, 19: 166‒72.клинической практике. Лечащий врач. 2013: 2.
14
Ait-Belgnaoui A, Han W, Lamine F et al. Lactobacillus farciminis treatment suppresses stress induced visceral hypersensitivity: a possible action through interaction with epithelial cell cytoskele-ton contraction. Gut 2006, 55: 1090‒4.
15 Gareau MG, Jury J, MacQueen G, Sherman PM, Perdue MH. Probiotic treatment of rat pups normalises corticosterone release and ameliorates colonic dysfunction induced by maternal separation. Gut 2007, 56: 1522‒8.
16 Kamiya T, Wang L, Forsythe P et al. Inhibitory effects of Lactobacillus reuteri on visceral pain induced by colorectal distension in Sprague-Dawley rats. Gut 2006, 55: 191‒6.
17 Verdu EF, Bercik P, Verma-Gandhu M et al. Specific probiotic therapy attenuates antibiotic induced visceral hypersensitivity in mice. Gut 2006, 55: 182‒90.
18 O'Mahony L, McCarthy J, Kelly P et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005, 128: 541‒51.
19 Whorwell PJ, Altringer L, Morel J et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol 2006, 101: 1581‒90ю
20 Mertz H, Naliboff B, Munakata J, Niazi N, Mayer EA. Altered rectal perception is a biological marker of patients with irritable bowel syndrome. Gastroenterology 1995, 109: 40‒52.
21 Knowles CH, Aziz Q. Basic and clinical aspects of gastrointestinal pain. Pain 2009, 141: 191‒209.
22 Gosselin RD, O'Connor RM, Tramullas M, Julio-Pieper M, Dinan TG, Cryan JF. Riluzole normalizes early-life stress-induced visceral hypersensitivity in rats: role of spinal glutamate reuptake mechanisms. Gastroenterology. doi: 10.1053/j. gastro.2010.03.003.
23 Myers B, Greenwood-Van Meerveld B. Role of anxiety in the pathophysiology of irritable bowel syndrome: importance of the amygdala. Front Enter Neurosci 2009, 1: 1‒10.
24 Butler RK, Finn DP. Stress-induced analgesia. Prog Neurobiol 2009, 88: 184‒202.
25 Pare WP, Redei E. Depressive behavior and stress ulcer in Wistar Kyoto rats. J Physiol Paris 1993, 87: 229‒38.
26 Lahmame A, del Arco C, Pazos A, Yritia M, Armario A. Are Wistar-Kyoto rats a genetic animal model of depression resistant to antidepressants? Eur J Pharmacol 1997, 337: 115‒23.
27 Malkesman O, Weller A. Two different putative genetic animal models of childhood depression ‒ a review. Prog Neurobiol 2009, 88: 153‒69.
28 Nielsen MA, Bayati A, Mattsson H. Wistar-Kyoto rats have impaired gastric accommodation compared to Sprague Dawley rats due to increased gastric vagal cholinergic tone. Scand J Gastroenterol 2006, 41: 773‒81.
29 Martinez V, Ryttinger M, Kjerling M, Astin-Nielsen M. Characterisation of colonic accommodation in Wistar-Kyoto rats with impaired gastric accommodation. Naunyn Schmiede- bergs Arch Pharmacol 2007, 376: 205‒16.
30 Gibney SM, Gosselin RD, Dinan TG, Cryan JF. Colorectal distension-induced prefrontal cortex activation in the Wistar-Kyoto rat: implications for irritable bowel syndrome. Neuroscience 2010, 165: 675‒83.
31 O'Malley D, Julio-Pieper M, Gibney SM, Dinan TG, Cryan JF. Distinct alterations in colonic morphology and physiology in two rat models of enhanced stress-induced anxiety and depression-like behaviour. Stress (Amsterdam, Netherlands) 2010, 13: 114‒22.
32 Hyland NP, Gibney SM, Gosselin RD, Dinan TG, Cryan JF. Assessment of colonic secretory function and faecal output in viscerally hypersensitive Wistar-Kyoto rats. Gastroenterology 2008, 134: A552‒3.
33 McKernan DP, Nolan A, Brint EK et al. Toll-like receptor mRNA expression is selectively increased in the colonic mucosa of two animal models relevant to irritable bowel syndrome. PLoS ONE 2009, 4: e8226.
34 Corr SC, Li Y, Riedel CU, O'Toole PW, Hill C, Gahan CG. Bacteriocin production as a mechanism for the antiinfective activity of Lactobacillus salivarius UCC118. Proc Natl Acad Sci USA 2007, 104: 7617‒21.
35 Sheehan VM, Sleator RD, Hill C, Fitzgerald GF. Improving gastric transit, gastrointestinal persistence and therapeutic efficacy of the probiotic strain Bifidobacterium breve UCC2003. Microbiology 2007, 153: 3563‒71.
36 Desbonnet L, Garrett L, Clarke G, Bienenstock J, Dinan TG. The probiotic Bifidobacteria infantis: an assessment of potential antidepressant properties in the rat. J Psychiatr Res 2008, 43: 164‒74.
37 O'Mahony SM, Marchesi JR, Scully P et al. Early life stress alters behavior, immunity, and microbiota in rats: implications for irritable bowel syndrome and psychiatric illnesses. Biol Psychiatry 2009, 65: 263‒7.
38 O' Mahony SM, Bulmer DC, Coelho AM et al. 5-HT2B Receptors modulate visceral hypersensitivity in a stress-sensitive animal model of brain-gut axis dysfunction. Neurogastroenterol Motil 2010, 22: 573‒8.
39 Quigley EM. Current concepts of the irritable bowel syndrome. Scand J Gastroenterol 2003, 237: 1‒8.
40 Mayer EA, Collins SM. Evolving pathophysiologic models of functional gastrointestinal disorders. Gastroenterology 2002, 122: 2032‒48.
41 Quigley EM. What is the evidence for the use of probiotics in functional disorders? Curr Gastroenterol Rep 2008, 10: 379‒84.
42 Zareie M, Johnson-Henry K, Jury J et al. Probiotics prevent bacterial translocation and improve intestinal barrier function in rats following chronic psychological stress. Gut 2006, 55: 1553‒60.
43 Madsen K, Cornish A, Soper P et al. Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology 2001, 121: 580‒91.
44 Greenwood-Van Meerveld B, Johnson AC, Kajs T et al. Probiotic bacteria normalize post-inflammatory visceral hyperalgesia in rats. Gastroenterology 2002, 122: A476.
45 Cryan JF, Valentino RJ, Lucki I. Assessing substrates underlying the behavioral effects of antidepressants using the modified rat forced swimming test. Neurosci Biobehav Rev 2005, 29: 547‒69.
46 Leventer SM, Raudibaugh K, Frissora CL et al. Clinical trial: dextofisopam in the treatment of patients with diarrhoea-predominant or alternating irritable bowel syndrome. Aliment Pharmacol Ther 2008, 27: 197‒206.
47 Gibney SM, Gosselin RD, Dinan TG, Cryan JF. Colorectal distension-induced prefrontal cortex activation in the Wistar Kyoto rat: implications for irritable bowel syndrome (IBS). Neuroscience 2010, 165: 675‒83.
48 Ait-Belgnaoui A, Eutamene H, Houdeau E, Bueno L, Fioramonti J, Theodorou V. Lactobacillus farciminis treatment attenuates stress-induced overexpression of Fos protein in spinal and supraspinal sites after colorectal distension in rats. Neurogastroenterol Motil 2009, 21: 567‒73, e18‒9.
49 Kunze WA, Mao YK, Wang B et al. Lactobacillus reuteri enhances excitability of colonic AH neurons by inhibiting calcium-dependent potassium channel opening. J Cell Mol Med 2009, 13: 2261‒70.
50 Ma X, Mao YK, Wang B, Huizinga JD, Bienenstock J, Kunze W. Lactobacillus reuteri ingestion prevents hyperexcitability of colonic DRG neurons induced by noxious stimuli. Am J Physiol 2009, 296: G868‒75.
51 Wang B, Mao YK, Diorio C et al. Lactobacillus reuteri ingestion and IK(Ca) channel blockade have similar effects on rat colon motility and myenteric neurones. Neurogastroenterol Motil 2010, 22: 98‒107, e33.